Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722278 · ClinicalTrials.gov registry record · Phase 3
A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
A Phase 3 study, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 222
- Enrollment target
NCT02722278 is a Phase 3 study that has completed, run by Clarus Therapeutics. The registered enrollment target is 222 participants.
The verdict
NCT02722278, a Phase 3 study, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 222 participants
- Enrollment target
Study Summary
A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Interventions
- DRUG Oral Testosterone Undecanoate
- DRUG Axiron Testosterone Topical Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02722278
The ClinicalTrials.gov registry entry for NCT02722278 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarus Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral Testosterone Undecanoate is the first listed.
NCT02722278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02722278 about?
NCT02722278 is a clinical study titled "A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men". A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
What is the current status of trial NCT02722278?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2016-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02722278?
The interventions under investigation include: Oral Testosterone Undecanoate (DRUG), Axiron Testosterone Topical Solution (DRUG).
Who is sponsoring clinical trial NCT02722278?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.